CliffBio
small molecule

RECARBRIO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Loss of exclusivityMarch 2033latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug detail

Brand nameRECARBRIO
Active ingredientCILASTATIN SODIUM; IMIPENEM; RELEBACTAM
StrengthEQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2019
Marketing statusRX

Listed patents

PatentExpiresType
8487093March 2033substance, product

Regulatory exclusivity

CodeExpires
GAINJuly 2029
NPPDecember 2028
NCEJuly 2024

More from MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found